FDA approved drug for Ulcerative Colitis
The occurrence of Inflammatory Bowel Disease (IBD) may be due to changes in economic development, improved hygiene and other lifestyle changes. The crude overall annual incidence was found to be 1.37 per 100,000 in Asia (Kasturiratne et al., 2014) followed by the prevalence of UC as 5.3 per 100,000 in Sri Lanka according to recent studies (Niriella et al., 2010). As treatment is limited for the treatment of ulcerative colitis, a drug, tofacitinib, used to treat rheumatoid arthritis has attained approval by the Food and Drug Administration (FDA) to treat
adults with moderate to severe ulcerative colitis. However, further research is required to analyse the efficacy of the treatment.